Highlights

  • ADPT shares gained 96.88% over the past year, outperforming Nasdaq index growth.
  • Quarterly revenue rose 51% to $71.68 million, surpassing analyst expectations.
  • Analysts revised the stock’s target price to $20.5, a 29.99% difference from current levels.

Adaptive Biotechnologies (NASDAQ:ADPT) has experienced notable fluctuations in recent trading sessions, with the stock declining 14.76% over the past five days compared with a 13.16% drop in the Nasdaq Composite index and a 10.92% decline in the biotechnology sector. Over a one-month period, shares fell 2.11%, while the broader index remained largely unchanged. Year-to-date performance shows a 2.89% decline for ADPT, contrasting with a 2.97% rise in the biotech sector.

Equity analysts have updated their price targets for Adaptive Biotechnologies in recent weeks. Piper Sandler, JPMorgan Chase & Co., Guggenheim, and BTIG Research all increased their price targets, with the current consensus at $20.5, reflecting a 29.99% difference from the current stock price of $15.77. Wall Street Zen recently adjusted its rating from “hold” to “buy,” while TD Cowen maintained its prior rating. Based on MarketBeat.com data, the stock holds an average rating of “Moderate Buy” from ten analysts.

The company reported earnings for the quarter ending February 5th, posting ($0.09) per share, exceeding the consensus estimate of ($0.19). Revenue increased 51% year-over-year to $71.68 million. Net margin remained negative at 21.48%, and return on equity was -48.73%. Analysts anticipate earnings per share of -0.92 for the current fiscal year.

Adaptive Biotechnologies continues to focus on its immune receptor sequencing platform, decoding T-cell and B-cell receptors to provide insights into immune-driven conditions. The company operates as a clinical-stage biotech firm specializing in leveraging the adaptive immune system to revolutionize disease diagnosis and therapy. By employing proprietary sequencing and analysis of immune receptors, it decodes T-cell and B-cell receptor genetics to pinpoint immune response patterns. The central technology platform delivers deep insights into immune-mediated diseases, facilitating enhanced monitoring precision and targeted treatment innovation.